Novartis AG
Close on Nov 2, 2026Market cap $308.21BP/E 22.6Yield –
Novartis Global Health Flagship Programs by Year
Global Health Flagship Programs — Malaria, Leprosy, Chagas, SCD (people)
Novartis Global Health Flagship Programs: 25,880,574 in FY2025, down 1.6% from a year earlier.
Where the FY2025 figure comes from
“| Patients reached through flagship programs | 25 880 574 | 26 310 195 | | 32 | ”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Reported in ESG Data Summary 2025 & Public Commitments.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Global Health Flagship Programs — Malaria, Leprosy, Chagas, SCD (people) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25,880,574 | -1.6% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 26,310,195 | -8.4% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 28,722,966 | -7.8% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2022 | Dec 31, 2022 | 31,157,087 | -4.7% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2021 | Dec 31, 2021 | 32,695,224 | -25.5% | Novartis Form 6-K (0001370368-24-000008) ↗ |
| FY2020 | Dec 31, 2020 | 43,912,152 | +191.4% | Novartis Form 6-K (0001370368-23-000009) ↗ |
| FY2019 | Dec 31, 2019 | 15,069,483 | – | Novartis Official IR / Sustainability Report — novartis-update-public-commitments-2025.pdf ↗ |
Cite this data
StockData. (2026). Novartis Global Health Flagship Programs, annual FY2019–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/access-patients-flagship
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.